Evidence map›Paper›PMID 40196074›Full record

ArticleCureus2025

Cutaneous Adverse Events Following COVID-19 Vaccination in Japan: A Questionnaire Survey.

Yuto Yamamura, Chisa Nakashima, Nana Kagawa, Yumi Aoyama, Akihisa Yamamoto, Hisao Kawahira, Yumiko Kubota, Saeko Nakajima, Takeshi Nakahara, Yoko Fuyuno and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Yuto YamamuraDermatology, Kindai University, Osaka, JPN.
Chisa NakashimaDermatology, Kindai University, Osaka, JPN.
Nana KagawaDermatology, Kindai University, Osaka, JPN.
Yumi AoyamaDermatology, Kawasaki Medical School, Kurashiki, JPN.
Akihisa YamamotoDermatology, Takarazuka City Hospital, Takarazuka, JPN.
Hisao KawahiraDermatology, Kagoshima University, Kagoshima, JPN.
Yumiko KubotaDermatology, Fukuoka Sanno Hospital, Fukuoka, JPN.
Saeko NakajimaDermatology, Kyoto University Graduate School of Medicine, Kyoto, JPN.
Takeshi NakaharaDermatology, Kyushu University, Fukuoka, JPN.
Yoko FuyunoDermatology, Kyushu University, Fukuoka, JPN.
Daisuke TsurutaDermatology, Osaka Metropolitan University, Osaka, JPN.
Ayaki MatsumotoDermatology, Osaka Metropolitan University, Osaka, JPN.
Risa MatsuoDermatology, Asahikawa Medical University, Asahikawa, JPN.
Riichiro AbeDermatology, Niigata University, Faculty of Medicine, Graduate School of Medical and Dental Science, Niigata, JPN.
Akihiko YukiDermatology, Niigata University, Faculty of Medicine, Graduate School of Medical and Dental Sciences, Niigata, JPN.
Hayato TakahashiDermatology, Keio University School of Medicine, Tokyo, JPN.
Chiaki TakahashiDermatology, Keio University School of Medicine, Tokyo, JPN.
Shin'Ichi ImafukuDermatology, Fukuoka University, Fukuoka, JPN.
Emi SatoDermatology, Fukuoka University, Fukuoka, JPN.
Susumu FujiwaraDermatology, Kobe University Graduate School of Medicine, Kobe, JPN.
Masahito YasudaDermatology, Gunma University Graduate School of Medicine, Gunma, JPN.
Yayoi TadaDermatology, Teikyo University School of Medicine, Tokyo, JPN.
Kotaro HayashiDermatology, Teikyo University School of Medicine, Tokyo, JPN.
Norito KatohDermatology, North Campus, Kyoto Prefectural University of Medicine, Kyoto, JPN.
Daisuke WatanabeDermatology, Aichi Medical University, School of Medicine, Aichi, JPN.
Atsushi OtsukaDermatology, Kindai University, Osaka, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We conducted a nationwide survey in Japan to clarify the clinical spectrum of these events. An initial questionnaire was sent to 126 dermatology facilities, and responses were obtained from 66 (52.4%). Among these responding facilities, the most commonly identified cutaneous adverse events after COVID-19 vaccination were urticaria (49 (74.2%)), delayed local reactions (37 (56.1%)), erythema multiforme (31 (47.0%)), and alopecia (30 (45.5%)). In the detailed survey, the primary adverse events were EM (19 (20.9%)), bullous pemphigoid (7 (7.7%)), and alopecia (6 (6.6%)). The mean latency from vaccination to onset was 13.1 days, and the mean duration of symptoms was 74.2 days. Although this study cannot establish a direct causal relationship between vaccination and adverse events, it highlights the need for dermatologists to recognize potential cutaneous reactions and provide appropriate care.

Indexed as

alopeciabullous pemphigoidcovid-19 vaccinecutaneous adverse eventserythema multiformepsoriasis

Identifiers

PMID40196074
PMCPMC11975142

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.